The Janus Kinase 1 Inhibitor Abrocitinib for the Treatment of Oral Lichen Planus

March 2023 in “ JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology ”

Farzan Solimani, Alberto Mesas-Fernandez, Amrei Dilling, Alexander Nast, Franz J. Hilke, Kamran Ghoreschi, Margitta Worm, Kamran Ghoreschi, Katharina Meier

We don't know much about this study yet.

We're maintaining the world's largest resposity of hair loss research. You can help out the community by sending a PDF of this study here . Not sure how to get a study's PDF? You can email the authors of the study.

View this study on onlinelibrary.wiley.com →

Discuss this study in the Community →

Related Community Posts Join

6 / 1000+ results

community Lilly to seek first approval of an autoimmune drug for hair loss

in Research/Science 19 upvotes 4 years ago

Eli Lilly's drug baricitinib showed effectiveness in treating alopecia areata, with higher doses resulting in significant hair regrowth compared to placebo. The treatment is not for male pattern baldness.

community Anyone with LPP have regrowth with Xeljanz?

in Treatment 3 upvotes 1 year ago

The conversation is about using Xeljanz for hair regrowth in individuals with LPP. The user is seeking experiences and expectations from others who have tried this treatment.

community Kintor Pharma Announced Successful Dosing of the First Patient for Acne Vulgaris Phase II Clinical Trial of KX-826

in Research/Science 12 upvotes 4 years ago

Kintor Pharma successfully dosed the first patient in a Phase II trial for KX-826 for acne vulgaris. Users are more interested in results for male pattern baldness (MPB).

community What are the odds baricitinib will get a topical otc version for androgenic alopecia?

in Research/Science 3 years ago

Baricitinib, approved for alopecia areata, might be considered for treating receding hairlines. The discussion is about the possibility of an over-the-counter topical version for androgenic alopecia.

community EMA is re-examining Winlevi (clascoterone at lower concentration)

in Treatment 8 upvotes 8 months ago

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

community I am a dermatologist with a clinical interest in alopecia. AMA

in Will treatment work for me? 3 years ago

In this conversation, 4990 discussed various treatments for hair loss, including oral minoxidil, PRP, transplan, Jak inhibitors, Dutasteride, Finasteride, Olumiant, Ketoconazole, RU58841, microneedling, baricitinib, and CCCA. They recommended scalp biopsies in unclear cases of DUPA, twice weekly to twice daily shampooing for topical minoxidil users, and two sessions spaced one month apart with follow up at month three to determine the effectiveness of PRP treatment.

Similar Research

5 / 1000+ results